Are antibody heavy and light chains really randomly paired, or are there rules?
We sat down with @josefng1.bsky.social, who introduced ImmunoMatch, a recently published framework for predicting heavy/light chain compatibility. This could be a new way to rank candidates before functional validation.
Our next High Affinity talks is tomorrow! 🎙️
We're welcoming Joseph Ng from UCL, creator of ImmunoMatch, a machine learning framework trained on paired human B cell sequences to predict chain compatibility and trace its role in B cell development and maturation.
Register here: bit.ly/4aZrM9o
Antibody discovery is moving fast.
But too many teams are still slowed down by fragmented tools, custom scripts, and bioinformatics bottlenecks.
That’s why we're hosting a virtual masterclass on how leading pharma and biotech teams are accelerating lead selection.
Sign up here: bit.ly/4ajVyVS
Choosing an Antibody Discovery Platform: A 2026 Landscape Review
We compared the current leaders based on five key criteria:
- End-to-end workflow coverage
- Scientist-first usability
- Functionality and visualizations
- Computational throughput
- Data control + flexibility
bit.ly/3LSJFhP
The most valuable AI in antibody discovery isn’t “generative.” It’s a filter
Labs don’t need 10,000 novel sequences we can’t make. We need AI to flag those that won't survive
The real ROI? Kill bad clones in silico
Saving weeks of failed experiments > hallucinating a “perfect” binder that crashes
The analysis gap is the biggest bottleneck in antibody discovery. Too often, teams must choose between fragmented scripts or opaque black-box tools.
Our app note shows how Platforma enables deep repertoire sequencing, functional clustering, and diversity-first selection to cut redundancy and risk.
Excited to host our first webinar of the year!
We're partnering with @miltenyibiotec.bsky.social to feature their new next-generation bulk RNA library preparation solution for TCR α/β profiling with advanced analysis and visualization in Platforma.
Register here: bit.ly/4jFH3Qv
Feb 5th @ 5 PM CET
A decade ago, immune repertoire sequencing was niche. Today, it’s population-scale.
From 3.5M TCR/BCR samples on MiXCR, key trends emerge:
• Bulk amplicon remains the workhorse
• Single-cell is growing fastest (>50% YoY)
• Academia customizes; industry standardizes
Full article:
bit.ly/4suV1ZG
What a year for our global research community 🌍
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
What if we’ve been studying TILs wrong?
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
Antibody discovery becomes far more powerful when functional assay data and NGS are brought together.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
Coupled with other filters for sequence liability and enrichment scores, this decision funnel guarantees a panel of leads that are both enriched and biologically diverse.
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
Last week during our antibody discovery webinar, we gave a live demo of our lead selection block.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
Last chance to register for our antibody discovery webinar tomorrow at 11 AM EST/ 5 PM CET!
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
Wrapping up our last Platforma Pioneers workshop at @bostonchildrens.bsky.social!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
Want to learn more about how top teams combine sequence, functional, and structural analysis to prioritize true therapeutic candidates?
Join our webinar next week.
bit.ly/4oY9s69
What everyone in antibody discovery should know:
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
MiXCR powered BCR extraction in this study, and with Platforma you can now go further—model structure, predict binding affinity, and rank top antibody leads by developability.
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
🧬 New deep learning model profiles antigen–antibody interactions at scale!
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
Platforma Pioneers Tour — UCSD & @lji.org
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
Want to accelerate your antibody discovery workflow?
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
This week, we kicked off our Platforma Pioneers academic tour at UCLA!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
RNA-seq to monitor minimal residual disease (MRD) in multiple myeloma?
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
We just wrapped up two impactful days at the Cell Symposium in Sitges, Spain with Cellecta! Was great to be face-to-face with researchers: live demos of Platforma, learning more about what others are working on, and sharing what our teams have been building.
Thanks to everyone who stopped by!
Proud to share a new study advancing non-invasive immune monitoring in cancer. Researchers found tumor-derived TCR clonotypes enriched in cfDNA and persisting >50 weeks in circulating T cells.
Proud that MiXCR powered large-scale TCR sequencing across tumor, blood, and cfDNA.
#cfDNA #TCRseq #TCR
Big news: we’ve launched an interactive demo on the Platforma website!
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
🧬 Join our team: We’re hiring a Scientific Sales Development Representative in Bilbao!
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84
🔬 Empowering the next generation of scientists!
Today, our team hosted a hands-on Platforma workshop at the University of Navarra, where researchers explored Platforma's powerful functionalities hands on with real datasets.
Thanks to everyone who joined!
#bioinformatics #NGS
🔬 Transform your B-cell research with Platforma - no coding required:
✔️ Annotate & build clonotypes with quality controls
✔️ Run clonality analyses across studies & patient groups
✔️ Cluster B cells, perform differential analysis, & explore UMAP
bit.ly/42QDhNb
Download today: platforma.bio
Although we couldn’t make it to #ASHG2025, our partner Illumina presented a fantastic study on accurate full-length V(D)J clonotype detection using high-quality long reads on the MiSeq™ i100.
We’re especially proud that MiXCR was used to enable precise immune repertoire profiling.
